Navigation Links
Astellas to Drive PGA TOUR's New Women's Initiative
Date:2/19/2013

PONTE VEDRA BEACH, Fla., and NORTHBROOK, Ill., Feb. 19, 2013 /PRNewswire/ -- The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today a 3-year agreement in which Astellas will champion the PGA TOUR's commitment to its new Women's Initiative.

"The Women's Initiative is an innovative platform designed to enhance the tournament experience for women and engage women in a meaningful and productive way in our tournament markets," said PGA TOUR Commissioner Tim Finchem . "As a leading pharmaceutical company strongly committed to enhancing health, particularly in the area of urological wellness, Astellas is an ideal partner to help drive our Women's Initiative and connect with women in settings they are already seeking out. We are delighted to collaborate with Astellas on this important and exciting venture."

The Women's Initiative is designed to provide women with information that promotes their overall well-being. Astellas and the PGA TOUR are working together to inform women about important health and wellness issues, encourage discussion on those topics and create opportunities to talk and learn about them.

"Astellas is proud to be partnering with the PGA TOUR on the Women's Initiative, which aims to help women obtain meaningful health-related and general wellness information," said Masao Yoshida , President and CEO, Astellas Pharma US, Inc. "The PGA TOUR's commitment to enhancing health and wellness aligns well with the Astellas focus on empowering and encouraging dialogue about the health and wellness issues that are not discussed often, such as overactive bladder, which affects more than 46 million adults in the U.S."

Key components of the Astellas Women's Initiative will include:

  • Astellas Presents Executive Women's Day—an expansion of the PGA TOUR's current Women's Day program that invites female business leaders from the community to attend a day-long forum focusing on professional, health-related and personal development discussions. Components include high-profile panelists, topic-specific breakout sessions, a keynote speaker and networking opportunities.
  • Astellas Pavilion—an onsite experience and meeting place for tournament participants to engage and learn about wellness issues. These special "women-friendly" facilities will provide information and education.

These 2013 TOUR season components will span 17 tournaments, beginning with the first Astellas Presents Executive Women's Day event on Feb. 26 at The Honda Classic Tournament in Palm Beach Gardens, Fla.

"We are very excited to embrace the new PGA TOUR Women's Initiative and thank Astellas for supporting this innovative program that will invite and attract new attendees to our events while educating them on their health and well-being," said Clair Petersen , tournament director of the John Deere Classic and chairman of the PGA TOUR Tournament Advisory Council.

About Astellas
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.us.   

The Astellas culture and brand is committed to building community, helping others, encouraging integrity and inspiring people to make a difference, today, tomorrow and every day.

About PGA TOUR
The PGA TOUR is the world's premier membership organization for touring professional golfers, co-sanctioning more than 100 tournaments on the PGA TOUR, Champions Tour, Web.com Tour, PGA TOUR Latinoamerica and PGA TOUR Canada.

The PGA TOUR's mission is to entertain and inspire its fans, deliver substantial value to its partners, create outlets for volunteers to give back, generate significant charitable and economic impact in the communities in which it plays, and provide financial opportunities for TOUR players.

Worldwide, PGA TOUR tournaments are broadcast to nearly 945 million households in 225 countries and territories in 32 languages. Virtually all tournaments are organized as non-profit organizations in order to maximize charitable giving. In 2012, tournaments across all Tours generated more than $122 million for local charitable organizations, bringing the TOUR's all-time total of charitable contributions to more than $1.8 billion.

The PGA TOUR's web site is PGATOUR.com, the No. 1 site in golf, and the organization is headquartered in Ponte Vedra Beach, FL.


'/>"/>
SOURCE Astellas
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
2. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Physicians Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021
9. The Medical Affairs Function Is a Key Differentiator for Pharma Product Success in Data-Driven Healthcare Market
10. The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market
11. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm®, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate ... year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children ... those children. James saw firsthand the effect of the critical funding gap for research ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) ... a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in ... “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... From a ... are released almost daily linking gut health to chronic disease, mental health and general ... Year ” as an important resolution to consider. , For one Charlottesville restaurant, good ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
Breaking Medicine News(10 mins):